A new mRNA vaccine, intismeran, demonstrated a significant reduction in melanoma recurrence risk, marking a breakthrough in personalized cancer treatment.
In an exciting development for melanoma treatment, a personalized mRNA vaccine named intismeran has shown promising results in a recent clinical trial. This innovative approach has been praised by oncologists, indicating a significant step forward in cancer vaccine technology.
Trial Overview
The late-stage trial involved 1,137 participants diagnosed with Stage 3 melanoma, wherein the cancer had spread to nearby lymph nodes or skin but had not reached distant organs. All participants had previously undergone surgery to remove their tumors and were receiving the immunotherapy drug Keytruda from Merck.
Out of the total, 757 patients received the personalized intismeran vaccine alongside Keytruda, while the remaining 380 participants were given a placebo. Dr. Robert Vonderheide, director of Penn Medicine’s Abramson Cancer Center, highlighted the findings as transformative for cancer treatment, noting a 42% reduction in the risk of cancer recurrence and death for those receiving both treatments.
How Intismeran Functions
Intismeran is unique because it is tailored to each individual’s tumor profile. It utilizes genetic sequencing to identify neoantigens—distinct abnormal proteins found in cancer cells that can be targeted by the immune system. This strategy trains the immune system to recognize and attack these specific markers, similar to how conventional vaccines train our bodies to fight infections.
Dr. Georgina Long, co-medical director at the Melanoma Institute Australia and leader of the trial, emphasized that, while surgery can remove visible tumors, microscopic cancer cells may still be present.